Oligochitosan modified albumin as plasmid DNA delivery vector: endocytic trafficking, polyplex fate, in vivo compatibility.

Cationic macromolecules condense DNA into small nanoparticles and kind polyplex. The composition of the polyplex determines the endocytic course of, the intracellular routing and the destiny of the polyplex. Beforehand, oligochitosan-modified vectors with completely different protein moieties are used as gene supply vector and the varieties of protein moiety can affect the endosome escape capability and transfection effectivity. Among the many modified vectors, oligochitosan-modified bovine serum albumin (BSA) confirmed 90% transfection efficeincy in comparison with the modified zein and ovalbumin.

These knowledge inspired us to research the mechanism of internalization concerned within the superior transfection effectivity of modified BSA/ plasmid polyplex. The impact of particular endocytic inhibitors was studied in two adherent cell traces. The caveolae-mediated and lipid-mediated pathways play a big position within the polyplex internalization. Subsequent, a colocation of polyplex with lysosome was investigated within the presence of LysoTracker utilizing confocal microscopy.

As much as 70% of polyplex efficiently escaped the lysosome with out degradation. 4 non-adherent cell traces confirmed above than 60% transfection effectivity at an optimized vector/plasmid ratio. Furthermore, no important hemolytic impact was noticed as much as 500 μg/mL of cationic BSA, indicating no detectable cell membrane disruption. General, the hybrid biomacromolecule confirmed good intracellular supply and security in a mice mannequin.

Optimization of peptide-plasmid DNA vectors formulation for gene supply in most cancers remedy exploring design of experiments.

The sphere of gene remedy nonetheless attracts nice curiosity resulting from its potential therapeutic impact in the direction of probably the most lethal ailments, equivalent to most cancers. For most cancers gene remedy to be possible and viable in a scientific setting, the design and growth of an acceptable gene supply system is crucial. Peptide primarily based vectors, particularly, disclose to be promising for therapeutic gene launch. Following this, two completely different peptides, RALA and WRAP5, have been investigated primarily relating to their capability to kind complexes with a p53 encoding plasmid (pDNA) with appropriate properties for gene supply.

To deal with this problem, and after an preliminary screening research targeted on the dependence of pDNA complexation capability with the nitrogen to phosphate teams (N/P) ratio, a design of experiments (DoE) instrument has been employed. For every peptide/pDNA system, parameters equivalent to, the buffer pH and the N/P ratio have been thought of the DoE inputs and the vector dimension, zeta potential and pDNA complexation capability (CC) have been monitored as DoE outputs. The primary purpose was to search out the optimum experimental situations to attenuate particle sizes, in addition to, to maximise the optimistic floor fees of the formulated nanosystems and maximize the pDNA CC.

By means of the DoE methodology utilized, the optimum RALA/pDNA and WRAP5/pDNA formulations have been revealed and present attention-grabbing options associated to peptide construction and pDNA complexation capability. This work illustrates the nice utility of experimental design instruments in optimizing the formulation of peptide/pDNA vectors in a minimal variety of experiments offering related data for the event of extra appropriate and environment friendly gene supply methods. The brand new insights achieved on these carriers clearly instigate deeper analysis on gene remedy.

Novel Expression Vectors Based mostly on the pIGDM1 Plasmid.

Escherichia coli is likely one of the most generally used hosts for the manufacturing of heterologous proteins. Inside this host, the selection of cloning vector constitutes a key issue for a passable amplified expression of a goal gene. We aimed to develop novel, unpatented expression vectors that allow the steady upkeep and environment friendly overproduction of proteins in E. coli. A collection of expression vectors primarily based on the ColE1-like pIGDM1 plasmid have been constructed. The vectors named pIGDMCT7RS, pIGDM4RS and pIGDMKAN carry numerous antibiotic resistance genes: chloramphenicol, ampicillin or kanamycin, respectively. Two derivatives comprise the inducible T7 promoter whereas the third one bears the constitutive pms promoter from a scientific pressure of Klebsiella pneumoniae.

 

The pIGDM1-derivatives are appropriate with different ColE1-like plasmids generally utilized in molecular cloning. The pIGDMCT7RS and pIGDM4RS vectors comprise genes encoding AGA and AGG tRNAs, which complement the scarcity of those tRNAs, growing the effectivity of synthesis of heterologous proteins. In conclusion, pIGDMCT7RS, pIGDM4RS and pIGDMKAN vectors, with considerably improved options, together with compatibility with overwhelming majority of different plasmids, have been designed and constructed. They allow a high-level expression of a desired recombinant gene and due to this fact represent a possible, precious instrument for pharmaceutical corporations and analysis laboratories for their very own analysis or for the manufacturing of recombinant biopharmaceuticals.

Minimal plasmids play a necessary position in lots of intermediate steps in molecular biology. For instance, they can be utilized to assemble constructing blocks in artificial biology or be used as intermediate cloning plasmids that are perfect for PCR-based mutagenesis strategies. A small spine additionally opens up for added distinctive restriction enzyme cloning websites. Right here we describe the technology of pICOz, a 1185-bp absolutely useful high-copy cloning plasmid with an prolonged a number of cloning web site. We imagine that that is the smallest high-copy cloning vector ever described.

Single Plasmid-Based mostly, Upgradable, and Backward-Suitable Adenoviral Vector Programs.

Current adenoviral vector methods have two drawbacks. It’s labor-intensive and time-consuming to load a transgene in these methods, and transgene-harboring vectors are lifeless ends: they can’t be reused to assemble a vector carrying one other transgene or attaining new traits. To beat these shortcomings, single plasmid-based adenoviral vector methods have been constructed the place a singular PmeI web site was positioned on the place for insertion of the exogenous gene.

c-Myc(MYC275) Antibody

BNC800275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF680 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC800275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF680 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC800699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF680 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC800699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF680 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC810275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF680R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC810275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF680R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC810699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF680R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC810699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF680R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC810909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF680R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC810909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF680R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC940275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF594 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC940275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF594 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC940699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF594 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC940699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF594 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC940909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF594 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC940909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF594 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC700275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF770 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC700275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF770 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC700699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF770 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC700699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF770 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC700909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF770 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC700909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF770 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC880699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF488A conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC880699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF488A conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC880909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF488A conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC880909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF488A conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC050699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF405M conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC050699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF405M conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC050909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF405M conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC050909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF405M conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC040699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF405S conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC040699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF405S conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC040909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF405S conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC040909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF405S conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC430275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF543 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC430275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF543 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC400275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF640R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC400275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF640R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC400699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF640R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC400699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF640R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC400909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF640R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC400909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF640R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC050275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF405M conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC050275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF405M conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNCB0275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), Biotin conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNCB0275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), Biotin conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCB0699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), Biotin conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCB0699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), Biotin conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCAP0909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCAP0909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCA0909-250 250uL
EUR 459.6
Description: Primary antibody against c-Myc(MYC909), APC conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNCAP0275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNCAP0275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCAP0699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCAP0699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCB0909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), Biotin conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCB0909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), Biotin conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC880275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF488A conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC880275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF488A conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNCR0275-250 250uL
EUR 459.6
Description: Primary antibody against c-Myc(MYC275), RPE conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCR0699-250 250uL
EUR 459.6
Description: Primary antibody against c-Myc(MYC699), RPE conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCR0909-250 250uL
EUR 459.6
Description: Primary antibody against c-Myc(MYC909), RPE conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNCP0275-250 250uL
EUR 459.6
Description: Primary antibody against c-Myc(MYC275), PerCP conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCP0699-250 250uL
EUR 459.6
Description: Primary antibody against c-Myc(MYC699), PerCP conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCP0909-250 250uL
EUR 459.6
Description: Primary antibody against c-Myc(MYC909), PerCP conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNUM0275-50 50uL
EUR 474
Description: Primary antibody against c-Myc(MYC275), 1mg/mL

c-Myc(MYC699) Antibody

BNUM0699-50 50uL
EUR 474
Description: Primary antibody against c-Myc(MYC699), 1mg/mL

c-Myc(MYC909) Antibody

BNUM0909-50 50uL
EUR 474
Description: Primary antibody against c-Myc(MYC909), 1mg/mL

c-Myc(MYC909) Antibody

BNCH0909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCH0909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNUB0909-100 100uL
EUR 250.8
Description: Primary antibody against c-Myc(MYC909), Concentration: 0.2mg/mL

c-Myc(MYC909) Antibody

BNUB0909-500 500uL
EUR 549.6
Description: Primary antibody against c-Myc(MYC909), Concentration: 0.2mg/mL

c-Myc(MYC275) Antibody

BNCH0275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNCH0275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCH0699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCH0699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNUB0275-100 100uL
EUR 250.8
Description: Primary antibody against c-Myc(MYC275), Concentration: 0.2mg/mL

c-Myc(MYC275) Antibody

BNUB0275-500 500uL
EUR 549.6
Description: Primary antibody against c-Myc(MYC275), Concentration: 0.2mg/mL

c-Myc(MYC699) Antibody

BNUB0699-100 100uL
EUR 250.8
Description: Primary antibody against c-Myc(MYC699), Concentration: 0.2mg/mL

c-Myc(MYC699) Antibody

BNUB0699-500 500uL
EUR 549.6
Description: Primary antibody against c-Myc(MYC699), Concentration: 0.2mg/mL

c-Myc(MYC275) Antibody

BNC040275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF405S conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC040275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF405S conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC550275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF555 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC550275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF555 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC550699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF555 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC550699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF555 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC610275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF660R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC610275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF660R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC610699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF660R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC610699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF660R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC610909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF660R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC610909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF660R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC680275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF568 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC680275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF568 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC470275-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF647 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC470275-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF647 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC470699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF647 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC470699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF647 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC550909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF555 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC550909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF555 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC430699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF543 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC430699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF543 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC430909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF543 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC430909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF543 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC680699-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF568 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC680699-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF568 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC680909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF568 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC680909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF568 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC470909-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF647 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC470909-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF647 conjugate, Concentration: 0.1mg/mL

anti- c-MYC antibody

FNab01791 100µg
EUR 702
Description: Antibody raised against c-MYC

Anti-c-Myc Antibody

PB9092 100ug/vial
EUR 400.8

Anti-c-Myc Antibody

PA1555 100ug/vial
EUR 352.8

Anti-c-MYC antibody

PAab01791 100 ug
EUR 494.4

Anti-C-myc Antibody

0912-2 100ul
EUR 189
Description: Myc is a family of regulator genes and proto-oncogenes that code for transcription factors. The Myc family consists of three related human genes: c-myc (MYC), l-myc (MYCL), and n-myc (MYCN). c-myc (also sometimes referred to as MYC) was the first gene to be discovered in this family, due to homology with the viral gene v-myc. In cancer, c-myc is often constitutively (persistently) expressed. This leads to the increased expression of many genes, some of which are involved in cell proliferation, contributing to the formation of cancer. A common human translocation involving c-myc is critical to the development of most cases of Burkitt lymphoma. Constitutive upregulation of Myc genes have also been observed in carcinoma of the cervix, colon, breast, lung and stomach. Myc is thus viewed as a promising target for anti-cancer drugs. Unfortunately, Myc possesses several features that render it undruggable such that any anti-cancer drugs for Myc dysregulation will require acting on the protein indirectly, i.e. targeting the mRNA for the protein rather than a small molecule that targets the protein itself. In the human genome, C-myc is located on chromosome 8 and is believed to regulate expression of 15% of all genes through binding on enhancer box sequences (E-boxes). In addition to its role as a classical transcription factor, N-myc may recruit histone acetyltransferases (HATs). This allows it to regulate global chromatin structure via histone acetylation.

Anti-c-myc antibody

STJ180021 0.1 ml
EUR 282

Anti-C-myc antibody

STJ160092 7 mL P
EUR 834

Anti-c-Myc antibody

STJ119460 100 µl
EUR 332.4
Description: The protein encoded by this gene is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. It functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma. There is evidence to show that alternative translation initiations from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site result in the production of two isoforms with distinct N-termini. The synthesis of non-AUG initiated protein is suppressed in Burkitt's lymphomas, suggesting its importance in the normal function of this gene.

Anti-c-Myc antibody

STJ97127 200 µl
EUR 236.4
Description: Rabbit polyclonal to c-Myc.

Anti-c-Myc antibody

STJ97962 100 µl
EUR 280.8
Description: Mouse monoclonal to c-Myc.

Anti-c-Myc antibody

STJ92355 200 µl
EUR 236.4
Description: Rabbit polyclonal to c-Myc.

Anti-c-Myc antibody

STJ92356 200 µl
EUR 236.4
Description: c-Myc is a protein encoded by the MYC gene which is approximately 48,8 kDa. c-Myc is localised to the nucleus. It is involved in signalling by NOTCH1, CDK-mediated phosphorylation and removal of Cdc6 and ERK signalling. It functions as a transcription factor that regulates transcription of specific target genes. It plays a role in cell cycle progression, apoptosis and cellular transformation. c-Myc is expressed in the nervous system, intestine, blood, liver and bone marrow. Mutations in the MYC gene may result in Burkitt lymphoma. STJ92356 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. This polyclonal antibody detects endogenous levels of c-Myc protein.

Anti-c-Myc antibody

STJ92357 200 µl
EUR 236.4
Description: Rabbit polyclonal to c-Myc.

Anti-c-Myc antibody

STJ92358 200 µl
EUR 236.4
Description: Rabbit polyclonal to c-Myc.

Anti-c-Myc antibody

STJ92359 200 µl
EUR 236.4
Description: Rabbit polyclonal to c-Myc.

anti- MYC tag antibody

FNab05456 100µg
EUR 658.5
Description: Antibody raised against MYC tag

anti- MYC-tag antibody

FNab05462 100µg
EUR 606.3
Description: Antibody raised against MYC-tag

Myc Antibody

abx242911-100ul 100 ul
EUR 477.6

Myc antibody

10R-10451 100 ug
EUR 522
Description: Mouse monoclonal Myc antibody

MYC antibody

10R-10606 100 ug
EUR 418.8
Description: Mouse monoclonal MYC antibody

MYC antibody

10R-1757 100 ug
EUR 614.4
Description: Mouse monoclonal MYC antibody

Myc antibody

10R-4914 100 ul
EUR 871.2
Description: Mouse monoclonal Myc antibody

Myc antibody

10R-4915 100 ul
EUR 829.2
Description: Mouse monoclonal Myc antibody

Myc antibody

10R-4916 100 ul
EUR 829.2
Description: Mouse monoclonal Myc antibody

Myc antibody

10R-7246 50 ug
EUR 337.2
Description: Mouse monoclonal Myc antibody

Myc antibody

20R-1901 50 ug
EUR 337.2
Description: Rabbit polyclonal Myc antibody

Myc antibody

20R-1902 50 ug
EUR 337.2
Description: Rabbit polyclonal Myc antibody

Myc antibody

20R-1903 50 ug
EUR 337.2
Description: Rabbit polyclonal Myc antibody

Myc antibody

20R-2131 50 ug
EUR 337.2
Description: Rabbit polyclonal Myc antibody

Myc antibody

20R-2218 50 ug
EUR 337.2
Description: Rabbit polyclonal Myc antibody

Myc antibody

20R-2219 50 ug
EUR 337.2
Description: Rabbit polyclonal Myc antibody

Myc antibody

20R-2220 50 ug
EUR 337.2
Description: Rabbit polyclonal Myc antibody

Myc antibody

70R-30593 100 ug
EUR 392.4
Description: Rabbit polyclonal Myc antibody

MYC Antibody

BF0467 200ul
EUR 540

The polymerase chain response (PCR) amplified transgene could possibly be cloned into PmeI-linearized beginning plasmids utilizing one step of Gibson meeting to generate goal adenoviral plasmids, which have been then prepared for virus rescue. This process was termed restriction meeting.

Leave a Reply

Your email address will not be published. Required fields are marked *